|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000180745 |
Summary for CLRN3 |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000180745 | Gene symbol | CLRN3 |
| Gene name | clarin 3 | |
| HGNC | 20795 | |
| Entrez ID | 119467 | |
| Gene type | protein_coding | |
| Synonyms | CLRN3|MGC32871|USH3AL1 | |
| UniProtAcc | Q8NCR9 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for CLRN3 |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor male and normal male samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| CLRN3 | 5.29e+02 | -2.01e+00 | 4.60e-01 | -4.37e+00 | 1.27e-05 | 4.94e-05 | LIHC |
| Differentially expressed gene analysis between tumor female and normal female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| CLRN3 | 1.21e+03 | 2.75e+00 | 5.62e-01 | 4.91e+00 | 9.32e-07 | 2.02e-05 | STAD |
| CLRN3 | 1.78e+03 | -1.20e+00 | 1.87e-01 | -6.42e+00 | 1.41e-10 | 8.17e-10 | COAD |
Top |
Sex-biased somatic mutation for CLRN3 |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for CLRN3 |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| KIRP | cg23817637 | chr10:127893165 | CGI:chr10:127907124-127907973 | promoter | 4.68e-01 | 3.21e-01 | 2.19e+00 | 2.82e-02 | 3.69e-02 | 1.47e-01 |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| KIRC | cg20424781 | chr10:127892586 | CGI:chr10:127907124-127907973 | promoter,exon,CDS,gene body | 6.50e-01 | 8.83e-01 | -1.99e+00 | 4.63e-02 | 4.67e-02 | -2.33e-01 |
| LUAD | cg23817637 | chr10:127893165 | CGI:chr10:127907124-127907973 | promoter | 7.71e-01 | 9.08e-01 | -4.45e+00 | 8.73e-06 | 3.76e-05 | -1.37e-01 |
| LUSC | cg23817637 | chr10:127893165 | CGI:chr10:127907124-127907973 | promoter | 6.75e-01 | 9.17e-01 | -3.22e+00 | 1.30e-03 | 3.09e-03 | -2.42e-01 |
| BLCA | cg23817637 | chr10:127893165 | CGI:chr10:127907124-127907973 | promoter | 7.03e-01 | 8.53e-01 | -2.73e+00 | 6.29e-03 | 9.77e-03 | -1.51e-01 |
| KIRP | cg23817637 | chr10:127893165 | CGI:chr10:127907124-127907973 | promoter | 3.21e-01 | 7.34e-01 | -3.33e+00 | 8.83e-04 | 1.64e-03 | -4.13e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
Top |
Exon skipping events with PSI in TCGA for CLRN3 |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for CLRN3 |
| ∗Please access CAeditome for RNA editing annotation. |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for CLRN3 |
| TFs related to CLRN3. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| ACC | MEF2D | CLRN3 | 7.06e+00 | 9.80e-01 | 6.41e+00 | 1.94e-02 | Male-biased |
| ACC | ZNF235 | CLRN3 | 5.04e+00 | 9.80e-01 | 4.36e+00 | 1.74e-02 | Male-biased |
| ACC | ZNF25 | CLRN3 | 6.47e+00 | 9.86e-01 | 5.74e+00 | 1.39e-02 | Male-biased |
| BLCA | MEF2C | CLRN3 | 6.11e+00 | 9.87e-01 | 5.35e+00 | 1.23e-02 | Male-biased |
| BLCA | ZNF235 | CLRN3 | 5.80e+00 | 9.95e-01 | 4.75e+00 | 4.39e-03 | Male-biased |
| BLCA | ZNF25 | CLRN3 | 7.04e+00 | 9.80e-01 | 6.40e+00 | 1.93e-02 | Male-biased |
| CHOL | CDX2 | CLRN3 | 6.64e+00 | 1.56e-02 | 7.47e+00 | 9.84e-01 | Female-biased |
| CHOL | HOXC10 | CLRN3 | 6.94e+00 | 1.22e-02 | 7.83e+00 | 9.88e-01 | Female-biased |
| CHOL | ZNF25 | CLRN3 | 6.11e+00 | 5.42e-03 | 7.21e+00 | 9.94e-01 | Female-biased |
| MESO | CDX2 | CLRN3 | 7.16e+00 | 9.90e-01 | 5.92e+00 | 9.26e-03 | Male-biased |
| MESO | FOXK2 | CLRN3 | 7.61e+00 | 9.85e-01 | 6.52e+00 | 1.48e-02 | Male-biased |
| MESO | HOXC10 | CLRN3 | 7.38e+00 | 9.90e-01 | 6.16e+00 | 1.00e-02 | Male-biased |
| MESO | MEF2D | CLRN3 | 7.14e+00 | 9.89e-01 | 5.95e+00 | 1.09e-02 | Male-biased |
| MESO | ZNF25 | CLRN3 | 6.80e+00 | 9.98e-01 | 5.10e+00 | 2.01e-03 | Male-biased |
| PCPG | CDX2 | CLRN3 | 7.81e+00 | 9.99e-01 | 6.31e+00 | 3.60e-04 | Male-biased |
| PCPG | FOXK2 | CLRN3 | 8.06e+00 | 9.96e-01 | 7.03e+00 | 3.73e-03 | Male-biased |
| PCPG | HIC2 | CLRN3 | 5.91e+00 | 3.03e-03 | 6.99e+00 | 9.97e-01 | Female-biased |
| PCPG | HNF4G | CLRN3 | 6.24e+00 | 1.76e-02 | 6.92e+00 | 9.82e-01 | Female-biased |
| PCPG | HOXC10 | CLRN3 | 8.07e+00 | 9.99e-01 | 6.69e+00 | 6.55e-04 | Male-biased |
| PCPG | MEF2D | CLRN3 | 7.72e+00 | 9.98e-01 | 6.49e+00 | 1.51e-03 | Male-biased |
| PCPG | RFX5 | CLRN3 | 7.22e+00 | 9.86e-01 | 6.49e+00 | 1.42e-02 | Male-biased |
| PCPG | SPZ1 | CLRN3 | 5.37e+00 | 3.56e-03 | 6.41e+00 | 9.96e-01 | Female-biased |
| PCPG | ZNF184 | CLRN3 | 7.28e+00 | 9.83e-01 | 6.59e+00 | 1.69e-02 | Male-biased |
| PCPG | ZNF235 | CLRN3 | 5.59e+00 | 9.98e-01 | 4.27e+00 | 8.73e-04 | Male-biased |
| PCPG | ZNF25 | CLRN3 | 7.51e+00 | 1.00e+00 | 5.62e+00 | 4.60e-05 | Male-biased |
| READ | HIC2 | CLRN3 | 7.11e+00 | 9.83e-01 | 6.41e+00 | 1.68e-02 | Male-biased |
| READ | MEF2C | CLRN3 | 4.91e+00 | 8.79e-03 | 5.77e+00 | 9.90e-01 | Female-biased |
| READ | SPZ1 | CLRN3 | 6.70e+00 | 9.95e-01 | 5.66e+00 | 4.22e-03 | Male-biased |
| READ | ZNF235 | CLRN3 | 3.39e+00 | 1.43e-03 | 4.75e+00 | 9.94e-01 | Female-biased |
| SARC | ZNF25 | CLRN3 | 6.68e+00 | 9.90e-01 | 6.11e+00 | 9.63e-03 | Male-biased |
| THYM | CDX2 | CLRN3 | 6.59e+00 | 3.77e-03 | 7.53e+00 | 9.96e-01 | Female-biased |
| THYM | FOXK2 | CLRN3 | 7.12e+00 | 5.20e-03 | 7.97e+00 | 9.95e-01 | Female-biased |
| THYM | HIC2 | CLRN3 | 6.58e+00 | 9.89e-01 | 5.92e+00 | 1.09e-02 | Male-biased |
| THYM | HOXC10 | CLRN3 | 6.91e+00 | 4.24e-03 | 7.81e+00 | 9.96e-01 | Female-biased |
| THYM | MEF2C | CLRN3 | 5.78e+00 | 1.11e-02 | 6.45e+00 | 9.88e-01 | Female-biased |
| THYM | MEF2D | CLRN3 | 6.66e+00 | 3.67e-03 | 7.60e+00 | 9.96e-01 | Female-biased |
| THYM | SPZ1 | CLRN3 | 5.92e+00 | 9.87e-01 | 5.28e+00 | 1.21e-02 | Male-biased |
| THYM | ZNF235 | CLRN3 | 4.98e+00 | 1.83e-03 | 6.10e+00 | 9.97e-01 | Female-biased |
| THYM | ZNF25 | CLRN3 | 6.02e+00 | 6.71e-04 | 7.40e+00 | 9.99e-01 | Female-biased |
| CLRN3 related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for CLRN3 |
| RBPs related to ES in CLRN3. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| CLRN3 related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs1248077 | chr10:119379533:G:A | - | -0.279103312182824 | 0.0036623289907716 | KIRP | Female-baised eQTL |
| rs12412018 | chr10:119381749:C:A | - | 0.279103312182824 | 0.0036623289907716 | KIRP | Female-baised eQTL |
| rs12243289 | chr10:127058425:T:C | - | 0.110008327754437 | 0.0202483745407683 | STAD | Female-baised eQTL |
| rs11018320 | chr10:127050064:C:G | - | 0.106240290797875 | 0.0490051760754175 | STAD | Female-baised eQTL |
| rs12262577 | chr10:127050508:C:G | - | 0.106240290797875 | 0.0490051760754175 | STAD | Female-baised eQTL |
| rs77994677 | chr10:127419553:G:T | - | 0.155022979639441 | 0.0157060310449674 | KIRC | Female-baised eQTL |
| rs3736938 | chr10:127415516:A:G | - | 0.122943308255923 | 0.0268331094322519 | KIRC | Female-baised eQTL |
| rs56408525 | chr10:127414612:T:G | - | 0.122617947355337 | 0.0278242974580796 | KIRC | Female-baised eQTL |
| rs72843704 | chr10:127414898:C:G | - | 0.122617947355337 | 0.0278242974580796 | KIRC | Female-baised eQTL |
| rs112065914 | chr10:122802517:T:A | - | 0.143434061892837 | 0.0449184474905026 | KIRC | Female-baised eQTL |
| rs74391260 | chr10:131120613:C:T | - | 0.162211110058884 | 0.0320254352174611 | COAD | Female-baised eQTL |
| rs74735319 | chr10:123293929:T:C | - | 0.146109201529543 | 0.0339529328688646 | COAD | Female-baised eQTL |
| rs17104935 | chr10:123287114:G:A | - | 0.135220817792331 | 0.0409927684921504 | COAD | Female-baised eQTL |
| rs7914110 | chr10:124911317:C:G | - | 0.108538965409105 | 0.0488986194399061 | COAD | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs697369 | chr10:123474015:A:C | - | -0.120707938028767 | 0.0100657849140884 | LIHC | Male-baised eQTL |
| rs7092671 | chr10:128236928:C:G | - | 0.0813826589988728 | 0.0105916197597534 | LIHC | Male-baised eQTL |
| rs705153 | chr10:123472684:T:G | - | -0.118499939107566 | 0.0127068603167754 | LIHC | Male-baised eQTL |
| rs1335010 | chr10:128237146:T:C | - | 0.0788096865003785 | 0.0149834025940401 | LIHC | Male-baised eQTL |
| rs79929789 | chr10:119430748:C:T | - | 0.140130532216434 | 0.0156221682728688 | LIHC | Male-baised eQTL |
| rs7477105 | chr10:129515560:C:T | - | 0.103650588886736 | 0.0268415770590916 | LIHC | Male-baised eQTL |
| rs9651394 | chr10:133611686:T:G | - | -0.0868581602005416 | 0.0359165377247588 | LIHC | Male-baised eQTL |
| rs6537616 | chr10:133614742:G:A | - | -0.0868581602005416 | 0.0359165377247588 | LIHC | Male-baised eQTL |
| rs705144 | chr10:123465997:C:T | - | -0.0775825090245937 | 0.0412636107024947 | LIHC | Male-baised eQTL |
| rs705146 | chr10:123466684:C:T | - | -0.0775825090245937 | 0.0412636107024947 | LIHC | Male-baised eQTL |
| rs12266590 | chr10:128239655:C:T | - | 0.134203528941776 | 0.042437030179037 | LIHC | Male-baised eQTL |
| rs66633114 | chr10:129500415:T:G | - | 0.0982271700927317 | 0.0478159703542807 | LIHC | Male-baised eQTL |
| rs12256165 | chr10:128249773:T:C | - | 0.114052167420308 | 0.0481357209700323 | LIHC | Male-baised eQTL |
| rs11199334 | chr10:120430797:T:A | - | -0.0469000028366962 | 0.0273947327270213 | COAD | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000180745 |
| CpG Site: cg23228835 | |
| Position to Gene: promoter | |
| Male Effect: -0.46434102908623 | |
| Female Effect: - |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg23228835 | chr10:127894188 | promoter | -0.46434102908623 | 5.16821909979639e-10 | -0.8428324875340264 | 7.331428944989161e-25 | PAAD |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of CLRN3 |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
